Jain, V., Giménez Arnau, A. M., Hayama, K., Reich, A., Carr, W., Tillinghast, J., . . . Haemmerle, S. (2024). Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks.
Citación estilo ChicagoJain, Vipul, et al. Remibrutinib Demonstrates Favorable Safety Profile and Sustained Efficacy in Chronic Spontaneous Urticaria Over 52 Weeks. 2024.
Cita MLAJain, Vipul, et al. Remibrutinib Demonstrates Favorable Safety Profile and Sustained Efficacy in Chronic Spontaneous Urticaria Over 52 Weeks. 2024.
Precaución: Estas citas no son 100% exactas.